Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors
详细信息 查看全文
- 作者：Jocelyn P. Wong1 ; 6 ; Jason R. Todd1 ; 6 ; Martina A. Finetti2 ; Frank McCarthy1 ; Malgorzata Broncel1 ; Simon Vyse1 ; Maciej T. Luczynski1 ; Stephen Crosier2 ; Karen A. Ryall3 ; Kate Holmes1 ; Leo S. Payne1 ; Frances Daley4 ; Patty Wai4 ; Andrew Jenks5 ; Barbara Tanos5 ; Aik-Choon Tan3 ; Rachael C. Natrajan4 ; Daniel Williamson2 ; Paul H. Huang1 ; 7 ; paul.huang@icr.ac.uk" class="auth_mail" title="E-mail the corresponding author
- 关键词：signal transduction ; receptor tyrosine kinase ; rhabdoid tumor ; tyrosine kinase inhibitor ; SWI/SNF ; SMARCB1 ; PDGFRα ; FGFR1 ; pazopanib
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：25 October 2016
- 年：2016
- 卷：17
- 期：5
- 页码：1265-1275
- 全文大小：4340 K
文摘
- •
Malignant rhabdoid tumors display coactivation of PDGFRα and FGFR1
- •
Dual inhibition of PDGFRα and FGFR1 leads to synergistic apoptosis
- •
FGFR1 inhibition overcomes acquired resistance to pazopanib treatment
- •
PDGFRα and FGFR1 are expressed in rhabdoid tumor patient specimens